Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequoia Spółka Z Ograniczoną OdpowiedzialnościąfiledCriticalSequoia Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL414902ApriorityCriticalpatent/PL414902A1/en
Publication of PL414902A1publicationCriticalpatent/PL414902A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Przedmiotem zgłoszenia jest kompozycja farmaceutyczna, zawierająca połączenie witamin K1 i K2, gdzie witamina K1 występuje w ilości 25 µg - 300 µg, a witamina K2 występuje w ilości 10 µg - 45 µg oraz jej zastosowanie, w celu profilaktyki krwawień i zapewnienia prawidłowej mineralizacji tkanki kostnej u niemowląt karmionych piersią,.The subject of the application is a pharmaceutical composition containing a combination of vitamins K1 and K2, where vitamin K1 is in the amount of 25 µg - 300 µg, and vitamin K2 is in the amount of 10 µg - 45 µg and its use for the prevention of bleeding and ensuring the proper mineralization of bone tissue in breast-fed infants.
PL414902A2015-11-232015-11-23Pharmaceutical composition containing combination of vitamin K1 and K2 and its application
PL414902A1
(en)
Topical pharmaceutical emulsion compositions comprising 3,5-dihydroxy-4-isopropyl-trans-stilbene and use thereof in the treatment or prophylaxis of dermatological conditions or disorders
Sweetener composition comprising allulose and a stevia extract; food product or beverage comprising the sweetener composition; tabletop sweetener; use of the sweetener composition.
use of a fermented ingredient and nondigestible oligosaccharide in the manufacture of a nutritional composition, method for enhancing immunoglobulin a secretion in a human subject aged 0 to 36, and method for enhancing mucosal immune defense in a human subject aged 0 to 36 months